Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Various wound bacteria” refers to the polymicrobial populations of aerobic and anaerobic bacteria frequently isolated from acute and chronic wounds[1]. Common constituents include Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacteriaceae (e.g., Klebsiella, Enterobacter, Escherichia coli), Streptococcus species, anaerobes such as Bacteroides, Prevotella, and Peptostreptococcus, as well as, less frequently, fungi (e.g., Candida species)[1][2]. These organisms can form robust biofilms that protect against antibiotics, impede wound healing, trigger inflammation, and contribute to tissue necrosis. The clinical term “various wound bacteria” cannot be mapped to a defined molecular target, and microbiological identification is performed at the genus or species level to guide therapeutic interventions[1][2].
Inhibition of cell wall synthesis (e.g., beta-lactams); Disruption of bacterial membrane (e.g., antimicrobial peptides); Inhibition of protein or nucleic acid synthesis; Disruption of biofilms
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Various wound bacteria.